Our partner is utilizing a powerful structure-based drug discovery engine; they create potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle.

This critical hire, reporting to the Chief Medical Officer, led the strategic direction and operational aspects for Regulatory Affairs, responsible for all regulatory aspects related to CMC, preclinical, and clinical development globally.